A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma
Status:
Enrolling by invitation
Trial end date:
2024-03-09
Target enrollment:
Participant gender:
Summary
A phase I dose-escalation, open-label, multicenter study to assess the safety, tolerability,
clinical activity, and pharmacokinetics (PK) of ZN-d5 in Chinese subjects with non-Hodgkin
lymphoma (NHL).